The Inspiration of the Design of Drug Medical Insurance Payment Standard System in typical countries and regions for China——From the perspective of original drug management

Corresponding author: shaorong, shaorong116@163.com

DOI: 10.12201/bmr.202409.00048

•  

  Abstract: OBJECTIVE To provide reference for the management of drug medical insurance payment standard under the background of the national drug centralized procurement policy. METHOD Research on the management experience of drug and medical insurance payment standard in typical countries and regions. RESULT There is a relatively complete drug medical insurance payment standard management system in the typical countries and regions of studied, refer to multiple factors such as the actual trading price in the market，and there are differences in drug medical insurance payment standard between generic and original drug. CONCLUSION It is recommended to improve relevant policy documents, and establish a scientific management system for drug medical insurance payment standards, establish a market-oriented mechanism for forming drug medical insurance payment standards through drug market price transactions, and refine classification management based on different attributes of different drugs such as generic drugs and original drugs；At the same time, under the current policy of implementing the same drug medical insurance payment standard for drugs with the same generic name of national drug centralized procurement, it is recommended to continue promoting and optimizing the consistency evaluation of generic drugs, achieving consistency in clinical efficacy between generic drugs and original drugs, in line with the current policy orientation of implementing the same drug medical insurance payment standard for generic drugs and original drugs.

  Key words: National Centralized Drug Procurement; Medical Insurance Payment Standard; Original Drug; Drug Price

  Submit time: 23 September 2024

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• SUN Wenjun, ZHAO Ziyin, CHENG Zheyu, LI Huining, ZHU He. Impact of the national centralized drug procurement policy on drug prices and utilization: a systematic review. 2023. doi: 10.12201/bmr.202303.00033

  WangBiao, Zhang Tiantian, Tang Xiaoyu, Jia Yun, Luo Li. A study of price reduction sustainability in national volume-based drug procurement. 2023. doi: 10.12201/bmr.202305.00008

  Sun Yan, Zhu Zheng, Yang Li. Influencing factors analysis on price reduction in national volume-based drug procurement.. 2022. doi: 10.12201/bmr.202203.00008

  WangBiao, Zhang Tiantian, Tang Xiaoyu, Jia Yun, Luo Li. Research on the price difference and regional distribution of selected drugs in Chinas centralized procurement. 2023. doi: 10.12201/bmr.202306.00008

  Tang Yuqing, Li Yinming, Chen Xizhuo, Xue Tianqin, Chen Hao. Analysis of the Execution of Centralized Drug Procurement Policy Based on Policy Implementation System Model. 2023. doi: 10.12201/bmr.202310.00002

  LI Zhao, Zhao Ke, Zhou Lulin, Chen Sheng. Research on the Comparison and Development Countermeasures of Pharmaceutical Group Purchasing Modes from the Perspective of the Normalization of National Centralized Procurement. 2021. doi: 10.12201/bmr.202109.00037

  Han Xinru, Zeng Kangni, Tan Jialong, Wang Jian. Lessons and Enlightments from International Experience of Health Insurance Drug Renewal Policy. 2024. doi: 10.12201/bmr.202407.00031

  LIU MINGZHU, LU YUN. Research on the Implementation Effect of Expiration of National Pharmaceutical Centralized Volume-based Procurement Based on Intermittent Time Series: A Case Study of Hebei Province. 2023. doi: 10.12201/bmr.202306.00007

  zhengwenyi, deng qing wen, xiayu, liuliu, chengyingyao, yangyi. Study on policy texts in the field of medical insurance payment system and treatment in China from the perspective of policy tools. 2024. doi: 10.12201/bmr.202402.00006

  xuguangjian, qiaoyukun. Research on the linkage mechanism between the adjustment of medical service price and the reform of medical insurance payment mode in China. 2021. doi: 10.12201/bmr.202104.00018

• ID	Submit time	Number	Download
  1	2024-04-28	bmr.202409.00048V1	Download

• Public  Anonymous  To author only Submit Comments